Algorithm identifies hypertensive patients who will benefit from intensive treatment

July 2, 2018 by Deborah Wormser, UT Southwestern Medical Center
Algorithm identifies hypertensive patients who will benefit from intensive treatment
The research team that developed the algorithm included (from left) Drs. Rohan Khera, Yang Xie, and Wanpen Vongpatanasin, and graduate student researcher Shidan Wang (not pictured). Credit: UT Southwestern

Using data from large clinical trials, UT Southwestern researchers developed a way to predict which patients will benefit most from aggressive high blood pressure treatment.

The machine learning algorithm they devised combines three variables routinely collected during clinic visits and demonstrates how the emerging field of bioinformatics could transform patient care. Their work, available online now and publishing July 15 in the American Journal of Cardiology, describes a risk prediction model in which patient age, urinary albumin/creatinine ratio (UACR), and cardiovascular disease history successfully identified hypertensive for whom the benefits of intensive therapy outweigh the risks.

"Large randomized have provided inconsistent evidence regarding the benefit of intensive lowering in hypertensive patients," said corresponding author Dr. Yang Xie, Director of the Quantitative Biomedical Research Center at UT Southwestern and of the University's Bioinformatics Core Facility. "To the best of our knowledge, this is the first study to identify a subgroup of patients who derive a higher net benefit from intensive pressure treatment."

Researchers used patient data from two National Institutes of Health-funded randomized controlled trials that tested intensive vs. standard blood pressure-lowering treatments—the Systolic Blood Pressure Intervention Trial (SPRINT) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The SPRINT trial included 9,361 nondiabetic hypertensive adults at an elevated risk of cardiovascular event, while ACCORD enrolled 10,251 patients with Type 2 diabetes.

"I think our algorithm can help us identify high-risk patients who will most likely benefit from intensive blood pressure reduction. Long-term intensive HBP drug therapy can reduce risk of heart failure and death, but it carries an increased risk of side effects," said co-author Dr. Wanpen Vongpatanasin, Professor of Internal Medicine and holder of the Norman and Audrey Kaplan Chair in Hypertension and the Fredric L. Coe Professorship in Nephrolithiasis Research in Mineral Metabolism.

The researchers' machine learning method determined three simple criteria to identify adults with who are at the highest risk for early major adverse cardiovascular events—such as cardiovascular death, heart attack, or stroke. Those criteria are: an age of 74 or older, a UACR of 34 or higher, and a history of clinical cardiovascular disease, such as heart disease, stroke, or heart failure. Patients who met one or more of the three criteria were predicted to be among a high-risk group who had a greater benefit from intensive blood pressure-lowering treatment. In contrast, the team found that patients younger than age 74 who had a UACR less than 34 and no history of may do equally as well with less intensive treatment.

"We feel that our findings have major clinical implications, since in addition to its predictive effects, the model generated here is simple and easy to implement in clinical practice without additional lab tests or computational tools," said Dr. Xie, who is also an Associate Professor of Clinical Sciences and Bioinformatics. "We hope that clinicians can someday use this algorithm to identify which patients should receive standard versus intensive treatment, and we hope to design a prospective clinical trial to further validate this algorithm."

Explore further: Intensive BP goals reduce risk of cardiovascular events

More information: Shidan Wang et al. Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering, The American Journal of Cardiology (2018). DOI: 10.1016/j.amjcard.2018.03.361

Related Stories

Intensive BP goals reduce risk of cardiovascular events

December 19, 2017
(HealthDay)—Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care.

How low is too low? Experts debate blood pressure targets in post-SPRINT era

May 4, 2018
Following the landmark SPRINT trial, there is a growing body of evidence for reducing systolic blood pressure targets, resulting in the development of new US guidelines. However, this has led to many questions about the impact ...

Renowned cardiologist says new blood pressure guidelines not good for all

March 7, 2018
One of the nation's leading cardiologists is challenging the new hypertension guidelines, perhaps sparing up to 10 million people from unnecessarily aggressive blood pressure treatments.

Intensive blood pressure lowering benefits patients with chronic kidney disease

June 23, 2017
Results from a recent clinical trial indicate that intensive blood pressure lowering reduces chronic kidney disease (CKD) patients' risks of dying prematurely or developing cardiovascular disease. The findings appear in an ...

Lower systolic blood pressure reduces risk of hypertension complication

October 13, 2015
Lowering systolic blood pressure below the currently recommended target can reduce the risk of left ventricular hypertrophy (LVH), the most common complication of high blood pressure, according to new research.

Intensive blood pressure can reduce risk of harm to heart muscle

May 22, 2017
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH). This condition, the ...

Recommended for you

Heart failure patients shouldn't stop meds even if condition improves: study

November 13, 2018
(HealthDay)—There's bad news for heart failure patients with dilated cardiomyopathy who'd like to stop taking their meds.

Bypass beats stents for diabetics with heart trouble: study

November 13, 2018
(HealthDay)—People with both diabetes and multiple clogged heart arteries live longer if they undergo bypass surgery rather than have their blood vessels reopened with stents, according to follow-up results from a landmark ...

Kawasaki disease: One disease, multiple triggers

November 12, 2018
Researchers at University of California San Diego School of Medicine, Scripps Institution of Oceanography, and international collaborators have evidence that Kawasaki Disease (KD) does not have a single cause. By studying ...

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

Study: How vitamin D and fish oil affect risk of heart attack, stroke and cancer

November 12, 2018
For years, it's remained an open question: What effects do dietary supplements such as high doses of vitamin D or omega-3 fatty acids derived from fish oil have on the risk of diseases such as heart attack, stroke and cancer? ...

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.